Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations

Abstract

French

Background:

Although the range of therapeutic options has expanded dramatically in recent years, topical agents remain ubiquitous and indispensable tools for treating psoriasis at all levels of severity. The 2009 Canadian psoriasis guidelines considered evidence supporting various monotherapies and combination regimens.

Objective:

Here we review all approved topical agents, including corticosteroids, calcineurin inhibitors, vitamin D analogues, and retinoids, used in psoriasis and develop additional treatment recommendations, using the Scottish Intercollegiate Guidelines Network (SIGN) system to evaluate strength of evidence, as in the original guidelines.

Conclusion:

We propose that topical treatments have a place in the long-term management of patients with moderate to severe plaque psoriasis, including those receiving concomitant photo- or systemic therapy. Topical agents are effective and appropriate treatments for psoriasis as long as the physician is attentive to signs of local adverse events and seeks opportunities to reduce the dose or treatment frequency during chronic use.

Get full access to this article

View all access options for this article.

References

Mahler

Jackson

Ijacu

. The burden of psoriasis and barriers to satisfactory care: Results from a Canadian patient survey. J Cutan Med Surg 2009;13:283–93.

Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. June 2009. Available at: http://www.dermatology.ca/psoriasisguidelines (accessed April 10, 2011).

Ali

Brodell

Balkrishnan

Feldman

. Poor adherence to treatments. Arch Dermatol 2007;143:912–5, doi:10.1001/archderm.143.7.912.

Nolan

Feldman

. Adherence, the fourth dimension in the geometry of dermatological treatment. Arch Dermatol 2009;145: 1319–21, doi:10.1001/archdermatol.2009.259.

Housman

Keil

Mellen

. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol 2003;49:79–82, doi:10.1067/mjd.2003.417.

Ference

Last

. Choosing topical corticosteroids. Am Fam Physician 2009;79:135–40.

Del Rosso

Friedlander

. Corticosteroids: Options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005;53(1 Suppl 1): S50–8, doi:10.1016/j.jaad.2005.04.030.

Stoughton

. Vasoconstrictor activity and percutaneous absorption of glucocorticosteroids. A direct comparison. Arch Dermatol 1969;99:753–6, doi:10.1001/archderm.99.6.753.

Regier

. Topical corticosteroids: Comparison chart. In: RxFiles drug comparison charts. 7th ed. Saskatoon (SK): Saskatoon Health Region; 2008. p. 20.

10.

Abma

Blanken

De Heide

LJM

. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002;60: 148–50.

11.

Coureau

Bussières

J-F

Tremblay

. Cushing's syndrome induced by misuse of moderate- to high-potency topical corticosteroids. Ann Pharmacother 2008;42:1903–7, doi:10.1345/aph.1L067.

12.

Semiz

Balci

Ergin

. Two cases of Cushing's syndrome due to overuse of topical steroid in the diaper area. Pediatr Dermatol 2008;25:544–7, doi:10.1111/j.1525-1470.2008.00735.x.

13.

Andres

Poncet

Farzaneh

Soto

. Short-term safety assessment of clobetasol propionate 0.05% shampoo: Hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol 2006;5: 328–32.

14.

Vazquez-Lopez

Marghoob

. Dermoscopic assessment of long-term topical therapies with potent steroids in chronic psoriasis. J Am Acad Dermatol 2004;51:811–3, doi:10.1016/j.jaad.2004.05.020.

15.

Mason

Cork

. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev (Online) 2009; (2):CD005028.

16.

Kragballe

Austad

Barnes

. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155–60, doi:10.1111/j.1365–2133.2006.07236.x.

17.

Veien

Olholm Larsen

Thestrup-Pedersen

Schou

. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol 1999;140:882–6, doi:10.1046/j.1365–2133.1999.02819.x.

18.

Faergemann

Christensen

Sjovall

. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000;14:393–6, doi:10.1046/j.1468–3083.2000.00099.x.

19.

Hanifin

Gupta

Rajagopalan

. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528–37, doi:10.1046/j.1365–2133.2002.05006.x.

20.

Katz

Hien

Prawer

. Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987;123: 1308–11, doi:10.1001/archderm.123.10.1308.

21.

Menter

Korman

Elmets

. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643–59, doi:10.1016/j.jaad.2008.12.032.

22.

Tanghetti

. The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol 2009;8(8 Suppl):S4–8.

23.

Molin

Cutler

Helander

. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 1997;136:89–93, doi:10.1111/j.1365-2133.1997.tb08752.x.

24.

Bruce

Epinette

Funicella

. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994;31:755–9, doi:10.1016/S0190–9622(94)70237–3.

25.

Bruner

Feldman

Ventrapragada

Fleischer

. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.

26.

Lebwohl

Ali

. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487–98; quiz 499–502, doi:10.1067/mjd.2001.117046.

27.

Lebwohl

Siskin

Epinette

. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268–9, doi:10.1016/S0190-9622(96)90349-7.

28.

Lebwohl

Yoles

Lombardi

Lou

. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: Effects on the duration of improvement. J Am Acad Dermatol 1998;39:447–50, doi:10.1016/S0190-9622(98)70323-8.

29.

Koo

Blum

Lebwohl

. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: Short- and long-term outcomes. J Am Acad Dermatol 2006;55:637–41, doi:10.1016/j.jaad.2006.05.026.

30.

Jemec

Ganslandt

Ortonne

. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. J Am Acad Dermatol 2008;59:455–63, doi:10.1016/j.jaad.2008.04.027.

31.

van de Kerkhof

Hoffmann

Anstey

. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. Br J Dermatol 2009;160:170–6, doi:10.1111/j.1365-2133.2008.08927.x.

32.

Menter

Abramovits

Colon

. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 2009;8:52–7.

33.

Ortonne

Humbert

Nicolas

. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(−1) ointment and calcipotriol 50 microg g(−1) ointment on chronic plaque psoriasis localized in facial, hairline, retro-auricular or flexural areas. Br J Dermatol 2003;148:326–33, doi:10.1046/j.1365-2133.2003.05228.x.

34.

Zhu

Wang

Zhao

. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007;21:466–72.

35.

Lebwohl

Ortonne

Andres

Briantais

. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis 2009;83:205–12.

36.

Lebwohl

Menter

Weiss

. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: Results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007;6: 428–35.

37.

Lebwohl

Goffe

Weiss

. A consecutive treatment regimen of clobetasol propionate 0.05% spray followed by calcitriol ointment 3 mg/g for the management of moderate to severe plaque psoriasis. J Am Acad Dermatol 2009;60 Suppl S:AB177.

38.

Luger

Paul

. Potential new indications of topical calcineurin inhibitors. Dermatology 2007;215 45–54, doi:10.1159/000102119.

39.

Freeman

Linowski

Brady

. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564–8, doi:10.1067/mjd.2003.169.

40.

Yamamoto

Nishioka

. Topical tacrolimus: An effective therapy for facial psoriasis. Eur J Dermatol 2003;13:471–3.

41.

Gribetz

Ling

Lebwohl

. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol 2004;51:731–8, doi:10.1016/j.jaad.2004.06.010.

42.

Dando

Wellington

. Topical tazarotene: A review of its use in the treatment of plaque psoriasis. Am J Clin Dermatol 2005;6:255–72, doi:10.2165/00128071-200506040-00006.

43.

Weinstein

Krueger

Lowe

. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85–92, doi:10.1016/S0190-9622(97)70216-0.

44.

Kaur

Dogra

Jain

Kumar

. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian J Dermatol Venereol Leprol 2008;74:471–4, doi:10.4103/0378-6323.44302.

45.

Lebwohl

Breneman

Goffe

. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;39:590–6, doi:10.1016/S0190-9622(98)70008-8.

46.

Gollnick

Menter

. Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999;140 18–23, doi:10.1046/j.1365-2133.1999.140S54018.x.

47.

Luger

Cambazard

Larsen

. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008;217:321–8, doi:10.1159/000155642.

48.

Poulin

Papp

Bissonnette

. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 2010;21:185–92.

49.

Kragballe

Hoffmann

Ortonne

. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: A randomized controlled trial. Br J Dermatol 2009;161: 159–66, doi:10.1111/j.1365-2133.2009.09116.x.

50.

Lee

Koo

. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: A Scholtz-Dumas bioassay comparison. J Drugs Dermatol 2009;8:751–5.

51.

Koo

JYM

. Relevance of the COBRA trial in current psoriasis practice. Cutis 2007;80:4–11.

52.

Menter

. Topical monotherapy with clobetasol propionate spray 0. 05% in the COBRA trial. Cutis 2007;80:12–9.

53.

Feldman

. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: Add-on therapy in the COBRA trial. Cutis 2007;80:20–8.

54.

Lebwohl

Colón

. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis. Cutis 2007;80:29–40.

55.

Jarratt

Clark

Savin

. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 2006;78:348–54.

56.

Beutner

Chakrabarty

Lemke

. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 2006;5:357–60.

57.

Anstey

Kragballe

. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006;45:970–5, doi:10.1111/j.1365-4632.2006.02939.x.

58.

Mohandas

Rai

Srinivas

. Halobetasol versus clobetasol: A study of potency. Indian J Dermatol Venereol Leprol 2009;75:186–7, doi:10.4103/0378-6323.48672.

59.

Goldberg

Hartdegen

Presbury

. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991;25: 1145–8, doi:10.1016/0190-9622(91)70313-Q.

60.

Mensing

Korsukewitz

Yawalkar

. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol 1991;25:1149–52, doi:10.1016/0190-9622(91)70314-R.

61.

Blum

Yawalkar

. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991;25:1153–6, doi:10.1016/0190-9622(91)70315-S.

62.

Woo

McKenna

. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: A prospective randomized placebo-controlled clinical trial. Br J Dermatol 2003; 149:146–50, doi:10.1046/j.1365-2133.2003.05380.x.

63.

Lebwohl

Menter

Koo

Feldman

. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004;50: 416–30, doi:10.1016/j.jaad.2002.12.002.

64.

Meola

Soter

Lim

. Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature. Arch Dermatol 1991;127: 1708–13, doi:10.1001/archderm.127.11.1708.

65.

Lebwohl

Papp

Han

. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: Results from the PHOENIX 1 trial. Br J Dermatol 2010;162:137–46.

66.

Saurat

J-H

Stingl

Dubertret

. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558–66, doi:10.1111/j.1365-2133.2007.08315.x.

67.

Menter

Tyring

Gordon

. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106–15, doi:10.1016/j.jaad.2007.09.010.

68.

Gordon

Korman

Frankel

. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006;54(3 Suppl 2):S101–11, doi:10.1016/j.jaad.2005.11.1088.

69.

Gordon

Langley

. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003;2:624–8.

70.

Reich

Nestle

Papp

. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005;366:1367–74, doi:10.1016/S0140-6736(05)67566-6.

71.

Lebwohl

Christophers

Langley

. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719–27, doi:10.1001/archderm.139.6.719.

72.

Thaçi

Ortonne

Chimenti

. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: The BELIEVE study. Br J Dermatol 2010;163:402–11, doi:10.1111/j.1365-2133.2010.09791.x.

73.

Perlmutter

Cather

Franks

. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008;58:116–24, doi:10.1016/j.jaad.2007.09.030.

74.

Pearce

Spencer

. Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat 2004;15:235–8, doi:10.1080/09546630410033745.

75.

Campione

Mazzotta

Paterno

. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. Acta Derm Venereol 2009;89:288–91, doi:10.2340/00015555-0585.

76.

Feldman

Koo

JYM

Johnson

Preston

. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis 2009;84:25–32.

77.

Gottlieb

Kerbleski

. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat 2009;20:100–8, doi:10.1080/09546630802441234.

78.

Habif

. Clinical dermatology. 5th ed. New York: Elsevier; 2010.

79.

Pauporte

Maibach

Lowe

. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat 2004;15:360–4, doi:10.1080/09546630410023566.